Izana Bioscience
Oxford
About Izana Bioscience
Izana Bioscience is a biopharmaceutical company focused on bringing innovative science to market. Izana Bioscience are developing a monoclonal antibody therapy, namilumab (IZN-101), targeting granulocyte macrophagecolony stimulating factor (GM-CSF). IZN-101 is under investigation for its use against the ongoing COVID-19 pandemic, to halt the rapid deterioration of patients with acute respiratory distress.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $1.8M
- Funding stage: M&A
- Last round: Grant (Dec 2017)
- Website: izanabio.com
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/izana-bioscience-162445 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.